Sitravatinib malate

• Target:

  VEGFR|||FLT|||Discoidin Domain Receptor (DDR) |||c-Kit|||Trk receptor|||TAM Receptor

• Related Pathways:

  Angiogenesis|||Tyrosine Kinase/Adaptors

• Bioactivity:

  Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.), shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

• Smiles:

  [C@H](CC(O)=O)(C(O)=O)O.C(NC1=CC(F)=C(OC2=C3C(C=C(S3)C4=CC=C(CNCCOC)C=N4)=NC=C2)C=C1)(=O)C5(C(NC6=CC=C(F)C=C6)=O)CC5

• Molecular Formula:

  C37H35F2N5O9S

• Molecular Weight:

  763.76

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  2244864-88-6